# Efficacy and Safety of Durvalumab in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis

> **NCT04356222** · PHASE4 · UNKNOWN · sponsor: **Hui Bu** · enrollment: 30 (estimated)

## Conditions studied

- Leptomeningeal Metastasis
- Durvalumab

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** methotrexate

## Key facts

- **NCT ID:** NCT04356222
- **Lead sponsor:** Hui Bu
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-06
- **Primary completion:** 2023-06
- **Final completion:** 2023-06
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2020-05-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04356222

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04356222, "Efficacy and Safety of Durvalumab in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04356222. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*